ZVRANasdaqPharmaceutical PreparationsFiscal year ends December 31
ZEVRA THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$10.16+0.22 (+2.21%)
Close on Oct 19, 2026
- Market cap
- $623.18M
- P/E (TTM)
- 10.9
- Dividend yield
- –
Share price
−$0.64 (−5.97%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
ZEVRA THERAPEUTICS, INC. grew revenue 119.4% to $136.07M over the twelve months to Jun 30, 2026. Free cash flow was $32.62M.
Revenue
$136.07M
+119.4% vs. a year earlier
Operating income
$82.38M
TTM Q2 2026
Free cash flow
$32.62M
TTM Q2 2026
EPS, diluted
$0.93
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $623.18M
- P/E ratio
- 10.9
- Price to sales
- 4.58
- Price to book
- 2.86
- Dividend yield
- –
- Free cash flow yield
- 5.24%
Fundamentals
- Revenue
- $136.07M
- Net income
- $58.26M
- EPS, diluted
- $0.93
- Free cash flow
- $32.62M
- Book value per share
- $3.55
- Diluted shares
- 61M
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Revenue
$136.07M+119.4% YoY
Gross profit
$129.89M+191.1% YoY
Operating income
$82.38M
Net income
$58.26M+2103.6% YoY
EPS, diluted
$0.93
Free cash flow
$32.62M
Reported periodTrailing twelve months